Mayo Clinic

Rochester, Minnesota
Director, Gene Expression Core
Associate Professor of Medicine

Research

Each year, about 8,000 patients in the United States and 40,000 worldwide are diagnosed with ALK-positive non-small cell lung cancer (NSCLC). This type of cancer involves molecular alteration to the anaplastic lymphoma kinase (ALK) gene that drives the formation of a tumor in the lung and is the focus of Dr. Jin’s research at the Mayo Clinic.

Dr. Jen and her team analyze the genetics of early-age cancer onset and lung cancers in non-smokers. With NFCR’s support, Dr. Jen and her team of scientists worked to develop a new approach to treat patients whose ALK-positive cancer became resistant to the target therapy crizotinib (Xalkori®). The team took tumor biopsies from patients whose ALK-positive tumors recurred and performed a next generation sequencing analysis to look for any new mutations that could be responsible for tumor resistance. Dr. Jen’s team then identified which genetic changes are associated with crizotinib resistance. The next step for Dr. Jen is identifying existing drugs that can target specific mutations identified during the genetic analysis. After that, the research obtained can help doctors create personalized prescriptions for each patient based on their unique genetic profile.

Bio

Jin Jen, M.D., Ph.D. attended Beijing Medical University and received her Ph.D. from the University of California. She completed her postdoctoral fellowship in oncology at the Johns Hopkins University School of Medicine before joining the faculty at the Mayo Clinic as an associate professor of medicine.

Dr. Jen is now a leading lung cancer researcher with extensive experience in genetic and gene expression analysis. She is a Principle Member of the Biomarker Discovery Program at the Mayo Center for Individualized Medicine.

Throughout her career, Dr. Jen has authored or co-authored of more than 100 manuscripts, published more than 133 papers and invented five published patents. She has also been awarded the 1991 Environmental Mutagen Society’s Alexander Hollaender Student Award and the 1997 James Valvano Award for Cancer Research.

Jin Jen, M.D., Ph.D.

Areas of Focus

Cancer Types

Years of NFCR Funding

2014 – 2016

Related Content

What is Genomic Sequencing, and Who Can Benefit?

There’s a paradigm shift taking place in the world of cancer treatment. Experts are moving away from an organ-focused approach to treatment, like using radiation to treat the specific area affected by cancer. Instead, they’re looking at genomic sequencing.  Genomics is the branch of molecular biology concerned with the structure, function, evolution, and mapping of an individual’s genes. Regarding cancer, genomics allows experts to examine DNA to determine an individual’s risk of cancer through genomic sequencing. This means that oncologists can provide more individualized treatment options for patients using precision medicine.  How can cancer risk be determined through genomic sequencing? Parents pass along many traits to their children, such as hair and eye color. Unfortunately, the risk of developing certain types of cancer can also pass along. By examining DNA, experts can identify certain changes in a person’s DNA known for increasing their risk of developing various types of cancer. However, not all cancers pass genetically. In fact, only five to ten percent of all cancers are believed to have an inherited gene mutation. It is important to note that no test can provide exact answers about a person’s inherited cancer risk. Genetic testing can tell whether a specific genetic mutation exists in the DNA. However, it cannot tell whether an individual will develop the disease associated with that mutation later in life or not. What is the benefit of genomic sequencing? Genomic sequencing cannot prevent a cancer diagnosis but can help identify cancer-related DNA mutations. This means an individual can implement precautionary measures. These measures could include making healthy lifestyle changes, such as exercising regularly, ceasing smoking, or reducing alcohol consumption. Depending on the type of mutation, medications may be available to reduce one’s risk of developing cancer. Similarly, genomic sequencing may highlight the option of surgery to remove an organ or gland to prevent cancer from forming or promote undergoing more health screenings regularly.  Who should utilize genomic sequencing? Experts typically only recommend genetic sequencing for patients whose families have a history of certain cancers or patterns of cancer. Doctors may order genetic testing for people that have: Multiple first-degree relatives with cancer diagnoses; Numerous relatives who have been diagnosed with the same cancer on one side of the family; A family history of cancers linked to a single gene mutation, such as breast cancer, ovarian cancer, or pancreatic cancer; Family member(s) who has been diagnosed with more than one type of cancer; Family member(s) who has been diagnosed with cancer at a younger age than typically seen for that cancer, such as colon cancer; Close relatives who have been diagnosed with cancers linked to rare hereditary cancer syndromes, such as Hereditary Breast & Ovarian Cancer Syndrome (HBOC), Cowden Syndrome, or Lynch Syndrome; or Family member(s) who has been diagnosed with rare cancer, such as breast cancer in a male. Can we expect more research in genomic sequencing?  National Foundation for Cancer Research (NFCR) is committed to advancing genomic research and its potential to be the future of developing treatment plans for cancer patients. As such, NFCR funds a dozen world-renowned researchers paving the way in genomic research. […]

Efficiently Eliminating Metastasized Melanoma Cells

The prevalence of skin cancer is rising at an alarming rate, with melanoma being the deadliest. Melanoma is renowned for quickly spreading to other organs (or metastasizing), drastically decreasing the likelihood of survival. Being able to stop the spread of melanoma cells is essential to save the lives of many patients; however, no researcher has been able to solve the puzzle – until now. With long-term support from the National Foundation for Cancer Research (NFCR), Dr. Daniel Haber and his team developed the CTC-iChip – a medical device to capture the few circulating tumor cells (CTCs) present in a standard blood sample from a patient. Circulating tumor cells are tumor cells that have become detached from the primary tumor and enter the blood circulation. While CTCs occur once in a billion cells and are extremely rare, they nevertheless may hold the key to metastasis—the stage responsible for most cancer deaths. Dr. Haber and his team developed methods to analyze the genes in CTCs, providing a liquid biopsy and an invaluable window into a patient’s cancer in real-time. Doctors may efficiently obtain critical information from their patient’s CTCs for life-saving treatment decisions in advanced cancer with the liquid biopsy. Though this significant breakthrough sparked excitement throughout the oncology world, Dr. Haber continued digging for more pieces to the puzzle. He honed in on the unique makeup of CTCs to understand what fueled the spread of these deadly cells and what inhibited it. Using samples from melanoma patients, the team found that the unique lipogenesis regulator (referred to as SREBP2) held an important role in combating the growth of CTCs. SREBP2 directly induces transcription of the iron carrier, which kicks off a chain reaction at a cellular level. This chain reaction causes resistance to ferroptosis inducers, a type of programmed cell death. The ability to manufacture these chain reactions within CTCs opens up a realm of therapeutic opportunities for patients with metastatic melanoma. While this discovery is highly significant in the war on cancer, it is only just the beginning of understanding how to reduce melanoma metastasis. Dr. Haber remains committed to solving more pieces of the puzzle. To support the work of Dr. Haber and other world-renowned researchers, please make a gift today. Additional Reads You May Enjoy: New Drug Makes Unresectable or Metastatic Ocular Cancer Treatable Catching Cancer Cells on Their Way to Spreading Detecting Skin Cancer with Artificial Intelligence and Other Game-Changing Technologies in Cancer Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.

New Treatment with Combined Immunotherapies is Effective for Drug Resistant Metastatic Lung Cancer